Acurx Pharmaceuticals, Inc. (ACXP) - Dilution Analysis

10-Q filing | 3.4M shares outstanding

S-1 filing: This prospectus relates to the resale of up to 1,300,000 shares of common stock by Lincoln Park Capital Fund, LLC.

S-1 filing: Acurx Pharmaceuticals, Inc. is offering up to 1,650,170 shares of common stock issuable upon exercise of series H warrants by selling stockholders.

8-K filing: Acurx Pharmaceuticals, Inc. entered into a Securities Purchase Agreement to issue and sell 816,068 shares of common stock at $3.03 per share and pre-funded warrants to purchase up to 9,017 shares of common stock at $3.029 per share in a registered direct offering, along with series H common warrants to purchase up to 1,650,170 shares of common stock in a concurrent private placement, for aggregate gross proceeds of approximately $2.5 million. ($2.5M proceeds)

10-K filing | 2.3M shares outstanding

S-1 filing: This S-1 filing describes a biopharmaceutical company's business, risks, and an offering for resale of common stock by Lincoln Park Capital Fund, LLC, under a previously established purchase agreement.

10-Q filing | 1.5M shares outstanding

8-K filing: Stock split 1-for-20 | Outstanding: 23,481,606 → 1,174,080

S-1 filing: The selling stockholders of Acurx Pharmaceuticals, Inc. may offer and resell up to 9,157,596 shares of common stock consisting of shares issuable upon exercise of series G-1 warrants, series G-2 warrants and placement agent warrants.

S-3 filing: Acurx Pharmaceuticals files an S-3 to offer up to $50,000,000 in common stock, preferred stock, and debt securities, either individually or in units, with the possibility of offering common stock or preferred stock upon conversion or exchange of debt securities.

8-K filing: Acurx Pharmaceuticals, Inc. entered into a warrant inducement agreement with a Holder, who exercised Existing Warrants to purchase 4,445,435 shares of Common Stock at $0.60 per share, in consideration for the Company's agreement to issue new warrants to purchase up to 8,890,870 shares of Common Stock. ($2.67M proceeds)

S-1 filing: This S-1 filing relates to the resale of up to 10,899,258 shares of Acurx Pharmaceuticals, Inc.'s common stock by Lincoln Park Capital Fund, LLC, with the company not receiving any proceeds from the sale.

10-Q filing | 22.4M shares outstanding

8-K filing: Acurx Pharmaceuticals, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, pursuant to which Lincoln Park committed to purchase up to $12.0 million in shares of common stock and issued 899,258 shares of common stock to Lincoln Park in consideration for its commitment to purchase shares under the Purchase Agreement.

S-1 filing: Acurx Pharmaceuticals, Inc. is offering 8,399,700 shares of common stock issuable upon exercise of warrants held by selling stockholders.

10-K filing | 16.2M shares outstanding

POS AM filing: The selling stockholders of Acurx Pharmaceuticals may offer and resell up to 2,610,841 shares of common stock consisting of shares issuable upon exercise of series E warrants and placement agent warrants.

8-K filing: Acurx Pharmaceuticals, Inc. agreed to issue and sell 2,150,000 shares of common stock at $0.40 per share and pre-funded warrants to purchase up to 595,000 shares of common stock at $0.3999 per share in a registered direct offering, along with series F common warrants to purchase up to an aggregate of 8,235,000 shares of common stock at an exercise price of $0.40 per share in a concurrent private placement. ($1.1M proceeds)

S-1 filing: Acurx Pharmaceuticals, Inc. is registering the resale of 2,610,841 shares of its common stock by selling stockholders, consisting of shares issuable upon exercise of series E warrants and placement agent warrants.

8-K filing: Acurx Pharmaceuticals, Inc. completed a registered direct offering of 2,463,058 shares of common stock at $1.015 per share, resulting in gross proceeds of approximately $2.5 million, and also issued warrants to purchase up to 2,463,058 shares of common stock and warrants to Wainwright to purchase 147,783 shares of common stock. ($2.5M proceeds)

10-Q filing | 16.4M shares outstanding

10-Q filing | 15.8M shares outstanding

10-Q filing | 15.5M shares outstanding

RW filing: The company has decided not to pursue the public offering and has requested withdrawal of the registration statement.

S-1/A filing: S-1/A filing for 12,019,230 shares of common stock at a proposed price of $2.08 per share.

S-1 filing: The filing is an S-1 registration statement for a common stock offering. The last reported sale price of the common stock on March 15, 2024 was $2.72 per share.

10-K filing | 14.5M shares outstanding

10-Q filing | 13.0M shares outstanding

10-Q filing | 12.2M shares outstanding

S-1 filing: Acurx Pharmaceuticals is registering the resale of 2,666,666 shares of common stock issuable upon exercise of warrants held by a selling stockholder.

8-K filing: Acurx Pharmaceuticals, Inc. entered into a Securities Purchase Agreement to issue and sell 601,851 shares of common stock at $3.00 per share and 731,482 pre-funded warrants at $2.9999 per pre-funded warrant, for gross proceeds of approximately $4.0 million, along with warrants to purchase 2,666,666 shares of common stock at $3.26 per share in a private placement. ($4.0M proceeds)

10-Q filing | 11.6M shares outstanding

10-K filing | 10.8M shares outstanding

10-Q filing | 11.1M shares outstanding

S-1 filing: Acurx Pharmaceuticals is registering the resale of 2,627,224 shares of common stock issuable upon exercise of warrants by selling stockholders.

10-Q filing | 10.3M shares outstanding

8-K filing: Acurx Pharmaceuticals, Inc. entered into Securities Purchase Agreements to issue and sell common stock and pre-funded warrants in a registered direct offering and a concurrent private placement. ($4.23M proceeds)

S-3 filing: Acurx Pharmaceuticals, Inc. files an S-3 form to register an indeterminate number of common stock and preferred stock for an aggregate initial offering price not to exceed $50,000,000.

10-Q filing | 10.2M shares outstanding

10-K filing | 10.2M shares outstanding

10-Q filing | 10.1M shares outstanding

10-Q filing | 9.9M shares outstanding

S-1/A filing: Acurx Pharmaceuticals, LLC is offering 2,500,000 shares of common stock on a firm commitment basis, assuming an initial public offering price per share of $6.00.

S-1 filing: Acurx Pharmaceuticals, LLC is offering 2,500,000 shares of common stock on a firm commitment basis, assuming an initial public offering price per share of $6.00.